Research and Development

Research and Development

  RAPID DEVELOPMENT OF THE ENTERPRISE DRIVEN BY CORE COMPETENCE OF SCIENCE

  With rapid development driven by core competence of science & technology,Yiling Pharmaceutical has in Shijiazhuang and Beijing established a world-class advanced high-tech new drug research and development platforms, an academicians workstation and a technical system for the R&D of new drugs following the guidance of TCM collateral disease theory innovation, which has the capability to research and develop Chinese herbal compounds,the multi-component TCM, the various kinds of single compound TCM new drugs and the super generics of western medicine.

 

 Hebei Key Lab for Collateral Diseases has passed National GLP Certifcation.

 

  PHARMACY ACADEMICIANS WORKSTATION

  The Yiling Academicians Workstation, as one of Hebei Biology & Pharmacy Academicians Workstations and of Shijiazhuang Biology & Pharmacy Academicians Workstations, relying on Yiling Pharmaceutical, has invited Chinese academicians and established the innovation technology system of “To research & develop key link centering on new drugs research & development” to give support for rapid development of Yiling Pharmaceutical. At the same time, It provides such services as science & technology consulting, talents training, program introducing and achievement transforming for biology & pharmacy industries in Hebei Province and research and develop comprehensive technical platforms for domestic top-rated and international innovative drugs.

 

The Yiling Academicians Workstation with foor area of 37,000 square meter

 

Yang Shengli, the academician of the Medical Pharmacy & Health Department of the Chinese Academy of Engineering, on behalf of more than 10 academicians is hired on contract

 

  The Yiling Academicians Workstation has set up 9 technology centers such as New Biology Drugs Technology Center, TCM Separation Technology Center, Medicine Screening Technology Center, Pharmacological Experiment Technology Center and Safety Evaluation Technology Center and has brought in a series of large high-technology science & technology devices including high throughput screening device, nuclear magnetic resonance device and liquid chromatography-mass spec-trometry device, thus establishing a comprehensive innovative drugs research & development system which is guided by collateral diseases theory innovation and is more complete, more systematic, more mature and more advanced.

 

 

  HIGH QUALITY RESEARCH AND DEVELOPMENT TEAM

 

 

  Yiling Pharmaceutical has built a research and development team of reasonable knowledge and age structure which is composed of academicians (Head persons) as well as returned experts, foreign experts, Doctors and Masters (Backbone force) and is engaged in such subjects as TCM, pharmacology, pharmacokinetics, pathology, biochemistry and Chinese medicine. And it is in cooperation with research and development institutions at home and abroad such as Peking University, Tsinghua University, China Medicine University, Dalian Institute of Chemistry and Physics of Chinese Academy of Sciences, University of Pittsburgh (in U.S.A.) and Stanford University (in California, U.S.A.).

 

 A Strong R&D Team of Reasonable Knowledge & Age Structure

 

 

  INTEGRATED INNOVATION ACHIEVEMENTS OF COLLATERAL DISEASES THEORY

  Shijiazhuang Yiling Pharmaceutical Co., Ltd. sticks to the strategy that scientifc and technological innovations lead to enterprise development and promotes TCM industrialization through TCM collateral diseases theory innovations. It first establishes a system of “Collateral Disease Syndrome and Treatment” during 2,000 years of TCM academic development and undertakes two national 973 Programs namely the “Basic Research on Establishment of Vascular-collateral Theory and Its Guidance for the Prevention and Treatment of Vascular Pathological Changes” and the “Ying-wei ‘You Luo Yi Tong, Jiao Hui Sheng Hua’ Research Based on Micro-Vascular Diseases Caused by Pathological Changes”. The academician Wu Yiling, chief scientist for national 973 programs, has written a book of 1.85 million characters titled Collateral Diseases Theory, and a book of 2.10 million characters titled Vascular-collateral Theory and the Collateral Disease Theory innovative teaching material for China colleges and universities of TCM in the 21st century. And the “Research on Collateral Disease Theory and Its Application” is granted the Second Award of National Science & Technology Progress Award. Also he has established a subject named Collateral Disease Theory which is recognized by the National TCM Management Bureau as a key subject, and has set up a branch of China Association of Chinese Medicine. With the setup of such branch in all provinces in China, research on collateral disease theory is on the rise both at home and abroad.

 

 

  IN 2005 AUTHORIZED TO UNDERTAKE THE NATIONAL 973 PROGRAM ON VASCULAR-COLLATERAL THEORY RESEARCH FOR THE FIRST TIME 

 

 

  The National 973 Program—“Basic Research on Establishment of Vascular-collateral Theory and Its Guidance for the Prevention and Treatment of Vascular Pathological Changes” successfully passed the acceptance organized by the Ministry of Science & Technology of P.R.C. and is rated highly by experts: putting forward the treatment rule titled “Ying-wei Cheng Zhi Tiao Ping” and the drugs use principle titled “Sou Ti Shu Tong”, having good curative effect on such diseases as arrhythmia and acute myocardial infarction and providing guidance for clinical and industrial development.

 

 

  IN 2011 AUTHORIZED TO UNDERTAKE THE NATIONAL 973 PROGRAM ON VASCULAR-COLLATERAL THEORY RESEARCH FOR A SECOND TIME 

 

 

  The national 973 Program—“Ying-wei ‘You Luo Yi Tong, Jiao Hui Sheng Hua’ Research Based on Micro-vascular Diseases Caused by Pathological Changes” is offcially launched, which appoints Wu Yiling as the Chief Scientist, authorizes Yiling Medical Research Institute as the organizer cooperated with 9 science research institutes like the Fuwai Cardiovascular Disease Hospital of Chinese Academy of Medical Sciences, Hebei Medical University, General Hospital of PLA, Fudan University.

  Under the guidance of the Ying-wei vascular-collateral theory, this program will further discuss the microscopic pathological features of micro-vascular pathological changes and the micro-vascular injury’s common pathological mechanism in such major diseases as acute myocardial infarction, cerebral infarction, arrhythmia, chronic heart failure and diabetic vascular complications, and work out the intervention strategy of curing heart diseases, brain diseases and kidney diseases simultaneously as well as the prevention of micro-vascular pathological changes and the new effective approaches to prevent major diseases.

 

 

  FIRST ESTABLISH A SYSTEM OF "COLLATERAL DISEASE SYNDROME AND TREATMENT", WRITE A SERIES OF BOOKS 

 

The Vascular-collateral Theory initially issued in the Great Hall of People in Beijing intensively refects the collateral disease research results

 

 

  ESTABLISHED A KEY SUBJECT NAMED COLLATERAL DISEASE THEORY WHICH IS RECOGNIZED BY THE STATE ADMINISTRATION OF TRADITIONAL CHINESE MEDICINE

 

 
 
 

  SET UP A COLLATERAL DISEASE BRANCH OF CHINA ASSOCIATION OF CHINESE MEDICINE TO PROVIDE GUIDANCE FOR NATIONAL COLLATERAL DISEASE WITH TRADITIONAL CHINESE MEDICINE AND WESTERN MEDICINE

 

 
 
 

  SET UP THE COLLATERAL DISEASES COMMITTEE OF WORLD ASSOCIATION TCM TO LEAD COLLATERAL DISEASES THEORY TO THE WORLD.DISEASE IN THE WORLD

 

 

  The Collateral Diseases Committee of World Association TCM establishes a high-level platform for medical experts and scholars from all over the world who engage in collateral disease research, and lead the subject of collateral disease theory to the world. The research results of collateral disease theory will bring hope to the solving of worldwide diffcult and complicated diseases.

 

 

  SET UP THE INTERNATIONAL CONFERENCE ON COLLATERAL DISEASES TO MAKE THE RESEARCH ON COLLATERAL DISEASE THEORY BE ON THE RISE BOTH AT HOME AND ABROAD

 

 

  Eight sessions of the International Conference on Collateral Diseases has been held since 2005. The conference has become the academic communication platform of collateral diseases with TCM and western medicine, making Tongluo medicine known to doctors both at home and abroad. Then Tongluo medicine is widely applied. More than 2,000 experts and scholars have attended the 8th International Conference on Collateral Diseases.